11.60USD+2.56%Mkt Cap: 864.49M USDP/E: —Last update: 2026-05-26
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat pat…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap864.49M USD
Enterprise Value565.79M USD
Revenue (TTM)97.36M USD
Gross Profit-148.16M USD
Net Income (TTM)-91.92M USD
Revenue/Share1.304 USD
Last Price11.60 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees260
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.17
PEG—
EV/EBITDA-2.80
EV/Revenue5.81
P/S8.58
P/B1.27
EPS (TTM)-2.29
EPS (Forward)-3.56
52W Range
6.92040% of range18.69
52W High18.69 USD
52W Low6.920 USD
Profitability
Gross Margin-152.18%
Oper. Margin-1724.14%
EBITDA Margin-207.27%
Profit Margin-73.20%
ROE-14.46%
ROA-10.50%
Growth
Revenue Growth-86.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-135.12M USD
CapEx (TTM)3.15M USD
FCF Margin-78.97%
FCF Yield-8.89%
Net Debt-269.79M USD
Net Debt/EBITDA1.34
Balance Sheet
Debt/Equity0.30
Current Ratio6.57
Quick Ratio6.22
Book Value/Sh8.843 USD
Cash/Share6.001 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)28.50 USD
Target Range14.00 USD – 43.00 USD
# Analysts12
Ownership
Shares Out.74.14M
Float54.50M
Insiders1.18%
Institutions115.49%
Short Interest
Short Ratio13.6d
Short % Float20.17%
Short % Out.14.20%
Shares Short10.53M
Short (prev mo.)11.30M
Technical
SMA 5012.22 (-5.1%)
SMA 20012.48 (-7.0%)
Beta0.93
S&P 52W Chg28.31%
Avg Vol (30d)757.94K
Avg Vol (10d)784.43K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—